



AR&E Docket No. 96700/819

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/624,080  
Applicant : Ganjum V. Kalpana  
For : INHIBITION OF HIV-1 VIRION PRODUCTION BY A  
: TRANSDOMINANT MUTANT OF INTEGRASE  
: INTERACTOR 1(INI1)/hSNF5  
Filed : July 21, 2003  
Examiner : Unknown  
Group Art Unit : 1645

REPLY TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION  
AND PRELIMINARY AMENDMENT

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 996371124 US

Date of Deposit: December 23, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Elie H. Gendloff

Signature: *Elie H. Gendloff*

Sir:

This Reply is in response to the Notice to File Missing Parts of Nonprovisional Application dated October 23, 2003 in the above-identified case (copy enclosed). The due date for this Reply is December 23, 2003. This Reply is therefore timely filed.

Small Entity Status

This application is a small entity application.

Declaration

Enclosed is a properly signed Declaration deemed to be in compliance with 37 C.F.R. 1.63.

Application No. : 10/624,080  
Applicant : Ganjum V. Kalpana  
For : INHIBITION OF HIV-1 VIRION PRODUCTION BY A TRANSDOMINANT  
: MUTANT OF INTEGRASE INTERACTOR1 (INI1)/hSNF5  
Filed : July 21, 2003  
Reply to Notice to File Missing Parts of Nonprovisional Application dated October 23, 2003  
Amendment dated December 23, 2003  
Page 2 of 7

#### Sequence Requirements

Applicants enclose herewith a sequence listing, in both computer readable and paper form, believed to put the subject application in compliance with 37 C.F.R. 1.821-1.825. Please enter the sequence listing into the application. The content of the sequence listing information recorded in computer readable form is identical to the written (on paper) sequence listing. This submission of the sequence listing includes no new matter.

#### Preliminary Amendment

Please enter the following amendments into the instant application.